256 related articles for article (PubMed ID: 20603657)
21. The need for balancing the regulation of pharmaceutical trademarks between the Food and Drug Administration and the Patent and Trademark Office.
Boring D; Doninger C
Food Drug Law J; 1997; 52(1):109-16. PubMed ID: 10346714
[No Abstract] [Full Text] [Related]
22. The Prescription Drug Marketing Act of 1987.
Greenberg RB
Am J Hosp Pharm; 1988 Oct; 45(10):2118-26. PubMed ID: 3228083
[TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
Binder GM
Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
[TBL] [Abstract][Full Text] [Related]
24. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
Patsner B
Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
[No Abstract] [Full Text] [Related]
25. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
26. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
Hogan GF
Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
[TBL] [Abstract][Full Text] [Related]
27. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
28. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
29. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
30. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
31. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
[TBL] [Abstract][Full Text] [Related]
32. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
Dauner DG; Dauner KN; Peterson ALH
Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
[TBL] [Abstract][Full Text] [Related]
33. Patents and the US FDA's definition of 'cocrystal': an ordinary and customary meaning?
Lindeman JA
Pharm Pat Anal; 2012 Nov; 1(5):513-5. PubMed ID: 24236917
[No Abstract] [Full Text] [Related]
34. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
35. Navigating the Hatch-Waxman Act's safe harbor.
Jones PB
Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
[No Abstract] [Full Text] [Related]
36. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
37. The regulation of drugs and biologics: fifty years into the future.
Kuhlik BN
Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
[No Abstract] [Full Text] [Related]
38. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
[TBL] [Abstract][Full Text] [Related]
39. The Prescription Drug User Fee Act of 1992. A 5-year experiment for industry and the FDA.
Shulman SR; Kaitin KI
Pharmacoeconomics; 1996 Feb; 9(2):121-33. PubMed ID: 10160091
[TBL] [Abstract][Full Text] [Related]
40. FDA reform signed into law. Food and Drug Administration.
James JS
AIDS Treat News; 1997 Dec; (No 284):6-7. PubMed ID: 11364915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
